Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$88.11M-$88.11MN/M vs Q3 2023 EPS Diluted-$0.63-$0.63N/M vs Q3 2023 Operating Income-$96,369,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$75,310,000N/M ended Sep 30, 2024 · filed Nov 6, 2024 · 37 d after period end